FOLFOX-4 Regimen as a first-line therapy for cuban patients with metastatic colorectal cancer

Leonardo Lami; Fernando Areces; Juan J Lence; María A Arbesú

2009, Number 3

<< Back Next >>

MEDICC Review 2009; 11 (3)

FOLFOX-4 Regimen as a first-line therapy for cuban patients with metastatic colorectal cancer

Lami L, Areces F, Lence JJ, Arbesú MA

Full text

How to cite this article

Language: English
References: 26
Page: 34-38
PDF size: 507.85 Kb.

ABSTRACT

Introduction In Cuba, colorectal cancer (CRC) is the malignant neoplasm with the fourth-highest incidence and third-highest mortality. Over one-third of CRC patients exhibit metastatic disease at the time of diagnosis. Standard treatment for metastatic CRC is a 5-fluorouracil (5-FU) + Folinic Acid (FA) continuous infusion regimen. International studies have shown, however, that systemic therapy using oxaliplatin combined with 5-FU and FA (FOLFOX-4) improves results in terms of both tumor response and survival in patients with inoperable metastatic CRC.
Objective Evaluate the FOLFOX-4 regimen as a first-line therapy for patients with inoperable metastatic CRC in Cuba.
Methods FOLFOX-4 therapy was administered to 56 patients with metastatic CRC, in a treatment cycle repeated every 2 weeks for 6–8 cycles. Patients were followed up for a period of 2 years.
Results Objective response was attained in 44.6% of patients, and complete response in 12.5%. Median duration of response and of progression-free survival was 9.6 and 8.9 months, respectively. Estimated survival at 2 years was 17% (95% CI: 6.89– 26.8). The most frequent adverse events were nausea, vomiting, diarrhea and neutropenia, the majority grade 1–2, according to Common Terminology Criteria for Adverse Events (CTCAE) classification.
Conclusions In patients studied, the FOLFOX-4 combination was shown to be an effective and well-tolerated therapeutic option for treating inoperable metastatic colorectal cancer.

REFERENCES

Jemal A, Murray T, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar–Apr;56(2):106–30.
DeVita VT, Hellman S, Rosenberg SA. Colon cancer. In: Pine J, Murphy J, Sebring S, editors. Cancer: Principles and Practice of Oncology. New York: Lippincott Williams & Wilkins;2005.
Anuario Estadístico de Salud 2007. Havana: Ministry of Public Health, National Statistics Division; 2007 [updated 2008 August 5; cited 2009 Jun 5]. Available from: http://www.sld.cu/ servicios/estadisticas/.
Meyerhardt JA, Mayer RJ. Systemic Therapy for Colorectal Cancer. N Engl J Med. 2005 Feb 3;352(5):476–87.
Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs. 1997 Oct;8(9):876–85.
Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993 Mar 20;306(6880):752–5.
Benites CM. Cáncer Colorrectal. Supervivencia. [thesis]. Havana (CU): National Institute of Oncology and Radiobiology;1986.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment Cancer Therapy Scale: development validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570–9.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000 Feb 2;92(3):205–16.
National Cancer Institute [Internet]. Rockville (MD): Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS (US);[updated 2008 May 29; cited 2007 June 17]. Available from: http://www.ctep.cancer.gov/.
Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated vs. fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst. 1994;86(21):1608–17.
Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000 Jan;18(1):136–47.
De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Jan;18(1):136–47.
Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX-6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 Jan 15;22(2):229–37.
Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004 Jan 1;22(1):23–30. Epub 2003 Dec 9.
Sobrero A, Guglielmi A, Grossi F, Puglisi F, Aschele C. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol. 2000 Oct;27(5 Suppl 10):S72–7.
Schmoll HJ. The role of Oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. Semin Oncol. 2002 Oct;29(5 Suppl 15):S34–9.
Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003 Aug;30(4 Suppl 15):S5–13.
De Gramont A, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow- up of 4 years. J Clin Oncol. 2005 Jun 1;23(16 Suppl):S3501.
Pérez-Staub N, Lledo G, Paye F, Gayet B, Flesch M, Cervantes A, et al. Surgery of colorectal metastasis in the Optimox 1 study. J Clin Oncol. 2006 Jun 20;24(18 Suppl):S3522.
Maindrault-Goebel F, Lledo G, Chibaudel B, Mineur L, Andre T, Bennamoun M, et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapyfree intervals after FOLFOX in patients with metastatic colorectal cancer. A GERCOR study. J Clin Oncol. 2006 Jun 20;24(18 Suppl):S3504.
Wiseman LR, Adkins JC, Plosker GL, Goa KL. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. Drugs Aging. 1999 Jun;4(6):459–75.
Omura K. Advances in chemotherapy against advanced or metastatic colorectal cancer. Digestion. 2008;77(Suppl 1):S13–22.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 2004 Jun 3;350:2335–42.
Moosmann N, Heinemann C. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Rev Anticancer Ther. 2008 Mar;8(3):319–29.
Crombet T, Torres L, Nenínger E, Catalá M, Solano ME, Perera A, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother. 2003 Mar–Apr;26(2):139–48.